Comparative Pharmacology
Head-to-head clinical analysis: GLYRX PF versus SCOPOLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYRX PF versus SCOPOLAMINE.
GLYRX-PF vs SCOPOLAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glycopyrrolate is a quaternary ammonium anticholinergic that inhibits muscarinic acetylcholine receptors, thereby reducing salivary secretion and blocking vagally mediated bronchoconstriction.
Scopolamine is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the action of acetylcholine at these receptors in the central nervous system and periphery.
Intravenous: 1 mg/kg of ideal body weight for 2 minutes, repeated in 2 hours if required; thereafter every 4 hours as needed.
1.5 mg transdermal patch applied to postauricular skin every 72 hours; for prevention of motion sickness, apply 4-5 hours before exposure. Alternatively, 0.3-0.65 mg intramuscularly or intravenously every 6-8 hours as needed; or 0.4-0.8 mg subcutaneously. Oral dose: 0.4-0.8 mg every 6-8 hours as needed.
None Documented
None Documented
Clinical Note
moderateScopolamine + Venlafaxine
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Venlafaxine."
Clinical Note
moderateScopolamine + Nefazodone
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Nefazodone."
Clinical Note
moderateScopolamine + Stiripentol
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Stiripentol."
Clinical Note
moderateScopolamine + Fesoterodine
Terminal elimination half-life of 4-6 hours; prolonged to 10-12 hours in renal impairment.
Terminal elimination half-life is approximately 2–4 hours in adults; in elderly or hepatic impairment, half-life may be prolonged.
Primarily renal excretion of unchanged drug (70-80%) and metabolites; minor biliary excretion (<10%).
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of elimination; biliary/fecal excretion accounts for the remainder.
Category C
Category A/B
Anticholinergic
Anticholinergic
"The risk or severity of adverse effects can be increased when Scopolamine is combined with Fesoterodine."